Baculovirus display of single chain antibody (scFv) using a novel signal peptide

BMC Biotechnology

Table 1 Affinity of scFvE2/p17 for different variants of the conserved C-terminal epitope of HIV-1 MAp17 (a).

Competitor	Epitope	Binding competition vs p17.1 (%)	Origin or HIV-1 isolate
Unrelated antigen (negative control)	CD147 (M6)	5.2 ± 2.9	-
17.1 (positive control)	DTGHSSQVSQNY	89.5 ± 1.6	LAI ^(b)
17.3	DTGHSSQISQNY	74.7 ± 10.2	1M-1005 ^(c)
17.7	DTGHSSQASQNY	44.0 ± 18.0	g22s2 ^(d)
17.8	DTGHSKQVSQNY	81.5 ± 9.5	4 ^(e)
17.9	DTGNNSQVSQNY	68.8 ± 2.2	pNL4.3 ^(f)
Inverted p17.1	YNQSVQSSHGTD	3.8 ± 1.5	-

^(a) Competition for scFvE2/p17 binding between the dodecapeptide p17.1 (corresponding to residues 121-132 in the MAp17 from HIV-1_LAI, used as immunogen) and other epitope variants was determined by ELISA, as examplified in Figure 4c. Data presented are m ± SEM (n = 3). Residues differing from the LAI prototype sequence are in bold.
^(b) [63].
^(c) [64].
^(d) [43].
^(e) [65].
^(f) [66].

ISSN: 1472-6750